Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study

Leukemia & Lymphoma
Tanya SkameneAnnette E Hay

Abstract

Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy. At one year, event-free survival (EFS) was 16% and overall survival (OS) was 28%. For PTCL patients, who received autologous stem cell transplant, two-year EFS and OS were 21% and 42%, respectively. Patients with PTCL had inferior OS (HR 0.49, p < .0001) and EFS (HR 0.53, p < .0001) compared to B-cell lymphoma. Outcomes for patients with R/R PTCL are poor with currently available therapies.

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C GuglielmiF Chauvin
Feb 5, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniS Tura
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
May 1, 2001·British Journal of Haematology·S SallahN P Nguyen
May 9, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A D ZelenetzC H Moskowitz
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RodríguezE Conde
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K J SavageJ M Connors
Nov 23, 2007·The New England Journal of Medicine·Rui WangJeffrey M Drazen
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie VoseUNKNOWN International T-Cell Lymphoma Project
Jul 16, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Gutiérrez-GarcíaA López-Guillermo
Feb 23, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Auayporn NademaneeStephen J Forman
Apr 24, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vivien MakKerry J Savage
May 1, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew A LunningSteven Horwitz
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sonali M SmithParameswaran N Hari
Feb 18, 2015·Annals of Hematology·Yasunori KogureMineo Kurokawa
Apr 15, 2015·Journal of the National Cancer Institute·Matthew C CheungUNKNOWN Committee on Economic Analysis and the Hematology Disease Site Committee, NCIC Clinical Trials Group
Dec 30, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jessica El-AsmarMohamed A Kharfan-Dabaja

❮ Previous
Next ❯

Citations

Jun 3, 2017·Leukemia & Lymphoma·N Nora Bennani, Stephen M Ansell
Aug 22, 2018·Chinese Medical Journal·Wen-Rong Huang, Dai-Hong Liu
Sep 17, 2020·F1000Research·Cheryl Foster, John Kuruvilla
May 20, 2021·Current Hematologic Malignancy Reports·Zakiah Al SomaliMahmoud Aljurf
Jun 10, 2021·Hematological Oncology·Stefano Luminari, Tetiana Skrypets

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved